These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26209551)

  • 21. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
    Patterson-Fortin J; Moliterno AR
    Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
    Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
    Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
    Zhang SJ; Abdel-Wahab O
    Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial MPN Predisposition.
    Tashi T; Swierczek S; Prchal JT
    Curr Hematol Malig Rep; 2017 Oct; 12(5):442-447. PubMed ID: 29027642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
    Mambet C; Matei L; Necula LG; Diaconu CC
    J Immunoassay Immunochem; 2016; 37(4):331-45. PubMed ID: 26890068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
    Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
    J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Application of genetic data to clinical practice of MPN].
    Edahiro Y
    Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.
    Morsia E; Torre E; Poloni A; Olivieri A; Rupoli S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular diagnostic criteria of myeloproliferative neoplasms.
    Andrews C; Conneally E; Langabeer SE
    Expert Rev Mol Diagn; 2023; 23(12):1077-1090. PubMed ID: 37999991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
    Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
    Loscocco GG; Coltro G; Guglielmelli P; Vannucchi AM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
    Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.